ATI RN
ATI Proctored Pharmacology 2023
1. A healthcare professional is reviewing the medical history of a client who has a new prescription for Metformin to treat type 2 diabetes. Which of the following findings should the healthcare professional report to the provider?
- A. Hemoglobin A1C of 7.5%
- B. Creatinine level of 1.2 mg/dL
- C. BUN level of 18 mg/dL
- D. Liver function tests showing AST of 50 units/L
Correct answer: D
Rationale: The correct answer is D. Elevated AST levels in liver function tests should be reported to the provider when a client is prescribed Metformin due to the potential risk of hepatotoxicity associated with the medication. Elevated Hemoglobin A1C (choice A), Creatinine level within normal range (choice B), and BUN level within normal range (choice C) are not directly concerning when initiating Metformin therapy.
2. When discussing immunizations, which vaccine series is typically completed before a child's first birthday?
- A. Pneumococcal conjugate vaccine
- B. Meningococcal conjugate vaccine
- C. Varicella vaccine
- D. Rotavirus vaccine
Correct answer: D
Rationale: The correct answer is D, Rotavirus vaccine. The rotavirus vaccine series is usually completed before a child's first birthday. It is given to infants in a series of doses starting at 2 months of age and must be completed by 8 months of age. This vaccine helps protect against severe diarrhea and vomiting caused by rotavirus infection, which is common in infants and young children. Choices A, B, and C are incorrect because the Pneumococcal conjugate vaccine, Meningococcal conjugate vaccine, and Varicella vaccine are not typically completed before a child's first birthday.
3. A client with a history of preterm labor is reviewing a new prescription for Terbutaline. Which of the following client statements indicates understanding of the teaching?
- A. I will increase my daily fluid intake to 3 quarts.
- B. I can increase my activity now that I've started on this medication.
- C. I will report increasing intensity of contractions to my doctor.
- D. I am glad this will prevent preterm labor.
Correct answer: C
Rationale: The correct answer is C. The client should report increasing intensity, frequency, or duration of contractions to the provider because these are manifestations of preterm labor. This response demonstrates the client's understanding of the importance of monitoring contractions and seeking appropriate medical attention. Choices A, B, and D are incorrect because increasing fluid intake, increasing activity, or assuming the medication will prevent preterm labor are not relevant actions in managing preterm labor or taking Terbutaline.
4. A client has a prescription for a Nitroglycerin transdermal patch. Which of the following instructions should be included by the healthcare provider?
- A. Apply the patch to a hairless area of the body.
- B. Remove the patch every 12 hours.
- C. Massage the patch after applying it.
- D. Place the patch over a hairless area of the body.
Correct answer: D
Rationale: The correct instruction for a Nitroglycerin transdermal patch is to place it over a hairless area of the body. This is essential to ensure proper adhesion and consistent absorption of the medication. Hair can impede the patch's ability to stick to the skin and deliver the medication effectively. Therefore, choices A, B, and C are incorrect. Applying the patch to the same site every day (Choice A) may lead to skin irritation, removing the patch every 12 hours (Choice B) is not typically recommended for Nitroglycerin patches, and massaging the patch after applying it (Choice C) could alter its integrity and affect drug delivery.
5. A client has a new prescription for Adalimumab for Rheumatoid Arthritis. Based on the route of administration of Adalimumab, which of the following should the nurse plan to monitor?
- A. The vein for thrombophlebitis during IV administration.
- B. The subcutaneous site for redness following injection.
- C. The oral mucosa for ulceration after oral administration.
- D. The skin for irritation following removal of a transdermal patch.
Correct answer: B
Rationale: Adalimumab is administered subcutaneously. Injection-site redness and swelling are common adverse effects. Therefore, the nurse should monitor the subcutaneous site for redness following the injection to assess for any potential issues or reactions.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access